कंपनी का अवलोकन
BGM Group Ltd. operates primarily as a pharmaceutical and chemical entity within the Chinese market, offering specialized oxytetracycline products designed to prevent and treat various diseases across livestock species such as chickens, turkeys, cattle, and swine, as well as in human applications. The company functions within the broader Healthcare sector, specifically categorized under the Drug Manufacturers - Specialty & Generic industry, which implies a focus on producing essential medicinal compounds rather than branded consumer pharmaceuticals. This enterprise holds a market capitalization of $61.37M, though specific annual revenue and employee count figures are not currently disclosed in the available public data. The market cap figure of $61.37M indicates that BGM Group Ltd. is classified as a small-cap entity, suggesting a lower market valuation relative to large-cap peers and potentially higher volatility due to its size and niche operational focus within the generic drug manufacturing landscape.
वित्तीय स्वास्थ्य
The available financial data indicates that the Trailing Twelve Months revenue, net income, and EBITDA figures are not explicitly quantified in the current dataset, necessitating a reliance on derived metrics to assess performance. The absence of reported free cash flow suggests that cash generation metrics are either negligible or not disclosed, which limits the immediate assessment of the company's financial flexibility for capital expenditure or debt repayment. A critical analysis of the margin structure reveals a gross margin of 0.0%, an operating margin of -15.6%, and a profit margin of 0.0%, indicating that the company's cost of goods sold and operating expenses exceed its total revenue, resulting in a loss position where every rupee of revenue does not cover the direct costs of production. When comparing the total cash on hand of $14.54M against the total debt of $1.78M, the company holds a net cash position, yet the debt-to-equity ratio stands at 0.97, suggesting a level of leverage that requires careful monitoring despite the positive net cash balance. The current ratio is not provided in the available facts, preventing a definitive statement on short-term liquidity coverage, though the net cash position generally mitigates immediate liquidity risks. Furthermore, the Return on Equity and Return on Assets are listed as N/A, which implies that the company is currently unable to generate positive returns on shareholder equity or total assets, reflecting the impact of the negative operating margin on overall management effectiveness and capital efficiency.
मूल्यांकन आकलन
The trailing P/E ratio and forward P/E ratio are both unavailable in the current dataset, meaning that traditional earnings-based valuation multiples cannot be calculated to compare the stock's price against its expected earnings trajectory. However, the price-to-book ratio is recorded at 0.17, which indicates that the market values the company at a significant discount to its book value, suggesting that investors are pricing in substantial operational risks or the lack of tangible asset appreciation. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA are also not available for citation, leaving the valuation assessment reliant on the price-to-book metric and historical trading ranges. The stock has exhibited extreme price volatility, with a 52-week high of $17.17 and a 52-week low of $0.27, placing the current trading environment in a context where the price could theoretically be anywhere within this vast range depending on market sentiment. While the beta value is not provided to quantify volatility relative to the broader market, the wide spread between the high and low prices suggests that the stock price is highly sensitive to market fluctuations and investor sentiment regarding the pharmaceutical sector.
Growth & Income
The revenue growth rate for the year-over-year period is recorded at 13.9%, indicating a positive expansion in sales volume or pricing power, whereas the earnings growth rate is not available due to the company's lack of reported net income. Since the earnings growth is unavailable and the company is reporting losses, the implication is that the recent revenue increase has not yet translated into profitability, a common scenario for companies scaling up generic drug production where revenue growth precedes margin realization. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means that any generated earnings are being retained and reinvested into the business operations rather than being distributed to shareholders. Consequently, the overall growth and income profile for BGM Group Ltd. is characterized by revenue expansion without current profit distribution, relying entirely on internal capital generation and potential future profitability to drive shareholder value.